OPN、CD44v6及MMP-2在肺鳞癌、腺癌中的表达及其临床意义  

Expression and clinicopathologic significance of OPN, CD44v6 and MMP-2 in squamous cell carcinoma and adenocarcinoma of the lung

作　　者：喻钧[1] 潘铁成[1] 李军[1] 魏翔[1] 陈涛[1] 胡敏[1] 宋定伟[1] 刘立刚[1] 陈鹏[1] 

机构地区：[1]华中科技大学同济医学院附属同济医院胸心外科,武汉430030

出　　处：《中国肺癌杂志》2006年第4期325-328,共4页Chinese Journal of Lung Cancer

摘　　要：背景与目的近年来关于细胞表面黏附分子(CD44)、基质金属蛋白酶(MMP)与肿瘤关系的研究比较多,而对骨桥蛋白(OPN)的研究却很少。本研究的目的是通过研究OPN、CD44v6及MMP-2在肺鳞癌、腺癌中的表达水平,了解它们与肺鳞癌、腺癌生长、浸润及转移的关系。方法采用免疫组化方法,对69例肺鳞癌、腺癌患者手术标本OPN、CD44v6和MMP-2进行检测。结果OPN、CD44v6和MMP-2表达率与患者组织学类型、TNM分期及淋巴结转移有密切关系(P<0.05),与细胞分化程度则无明显关系(P>0.05)。OPN与CD44v6、MMP-2的表达均呈正相关,CD44v6与MMP-2表达之间无相关性。结论OPN、CD44v6和MMP-2的表达同肺癌病理类型、分期、淋巴结转移有密切关系,可能作为临床评估肺鳞癌、腺癌进展及预测肿瘤转移潜能的指标。Background and objective There are a lot of studies on relationship of surface adhesion molecule （CD44） and matrix metalloproteinase （MMP） with tumors in recent years, however study on osteopontin （OPN） is still few. The aim of this study is to investigate the levels of OPN, CD44v6 and MMP-2 in squamous cell carcinoma and adenocarcinoma of the lung, and to clearly understand their roles in growth, invasion and metastasis of squamous cell carcinoma and adenocarcinoma. Methods OPN, CD44v6 and MMP-2 were detected in 69 patients with squamous cell carcinoma and adenocarcinoma by immunohistochemical method. Results The expression rate of OPN, CD44v6 and MMP-2 was significantly related to histological classification, TNM stages and lymph node metastasis （P〈0.05）, but not to cell differentiation （P〉0.05）. There was a positive correlation between OPN and CD44v6 expression （P〈0. 001）, as well as between OPN and MMP-2 expression （P〈0. 001）. There was no correlation between CD44v6 and MMP-2 expression. Conclusion OPN, CD44v6 and MMP-2 expression is related to the histology, TNM stages and lymph node metastasis of lung cancer. They might be used as clinical indicators to predict the progress and metastatic potential for squamous cell carcinoma and adenocarcinoma of the lung.

关 键 词：肺肿瘤/鳞癌 肺肿瘤/腺癌 骨桥蛋白 MMP-2 CD44V6 免疫组化 

分 类 号：R734.2[医药卫生—肿瘤]